Aurora (ACB) Q4 2026 Earnings Transcript

Aurora Cannabis reported fiscal 2026 net revenue of CAD 321 million, up 11%, and adjusted EBITDA of CAD 54 million, up 32%, with CAD 165 million in cash and no debt. However, fiscal 2027 guidance calls for lower revenue and adjusted EBITDA after a 30% reduction in Canadian medical reimbursement rates, partially offset by international growth in Germany and Poland. Management is also exiting low-margin Canadian consumer and propagation businesses and integrating the CAD 26.5 million Safari Flower acquisition to expand EU GMP capacity.

Analysis

The key takeaway is not the headline revenue growth, but the company’s intentional migration from a diversified cannabis operator into a concentrated medical-export platform with better margin durability and lower channel conflict. That should structurally improve quality of earnings over time, but FY27 looks like a transition year where top-line dilution from reimbursement changes, consumer exits, and asset divestitures masks the underlying mix shift. The real question is whether international growth can outrun the Canadian reimbursement reset before the market loses patience on multiple compression.

The second-order winner is not just Aurora; it is any supplier with GMP capacity, genetics, and regulatory moats in Germany and Poland. If Aurora’s Leuna expansion and Safari integration work, the bottleneck becomes certified supply rather than demand, which should pressure smaller European importers and Canadian peers lacking audited capacity. Conversely, if German pricing continues to soften in the value tier, Aurora’s premium/core exposure should outperform the broader market, but only if it defends share without chasing price.

A contrarian read: the reimbursement cut may be less of an existential hit than management frames, because the company appears to be using it as a catalyst to shed low-return revenue and rationalize capital. That said, the market may underappreciate working-capital and SG&A drag from scaling international distribution before the revenue base fully re-accelerates. The balance-sheet strength gives them optionality, but it also raises the risk of value-destructive M&A if management tries to buy growth too aggressively during a reset year.

Key Decisions for Investors

• Hold ACB only as a tactical long into FY27 volatility; better entry is on a post-guidance selloff if the stock re-rates to distressed multiples despite no balance-sheet stress. Risk/reward improves only if international growth offsets at least half of the Canadian reimbursement hit within 2-3 quarters.
• Long ACB vs short a U.S./Canada recreational-exposed cannabis peer basket for a 6-12 month pair trade. Thesis: Aurora’s medical-only mix, GMP moat, and no-debt balance sheet should outperform operators still exposed to price compression and consumer segment erosion.
• Buy ACB Jan-2027 call spreads rather than common stock if implied volatility is elevated. This captures the upside from a successful Safari/Leuna integration while capping downside if FY27 proves a prolonged reset.
• Watch JAZZ as a beneficiary if broader cannabinoid legitimacy improves and pharma partnership optionality gets repriced. Any U.S. medical-regulatory opening could create asymmetric upside for established cannabinoid therapeutics exposure before it helps cultivators materially.
• Avoid chasing ACB on near-term product-launch optimism; the next catalyst that matters is evidence of German and Polish revenue acceleration over the next 1-2 quarters, not rhetoric about long-term market opportunity.